Literature DB >> 19837754

Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.

Hui Wang1, Jinming Zhang, Jiahe Tian, Baolin Qu, Tianran Li, Yingmao Chen, Jian Liu, Shan Wang.   

Abstract

UNLABELLED: (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) have been proven useful in diagnosing and staging many types of cancer but with emphasis on different aspects of tumor biology. The aim of the current study was to evaluate whether (18)F-FDG and (18)F-FLT can be used complementarily in monitoring the biologic characteristics of colorectal cancer (CRC).
METHODS: Human CRC cell lines SW480 and SW620 of the same genetic origin but different metastatic potential were cultured and implanted into nude mice to create CRC models. Uptake of (18)F-FDG and (18)F-FLT in SW480 and SW620 cells in vitro was assessed after incubation with radiotracers for 0, 30, 60, 90, and 120 min. In vivo imaging of SW480 and SW620 tumor-bearing mice was performed using small-animal PET/CT at 60 min after injection of each tracer. A region of interest was drawn over tumor and background to calculate the tumor-to-nontumor ratio (T/NT) using software on reconstructed images. Tumor growth rate, metastatic status, and survival time were assessed in tumor-bearing mice. The relationship between uptake of the tracers, metastatic capability, and tumor marker expression was evaluated using linear regression.
RESULTS: SW480 tumors grew more quickly than SW620 tumors (t = 3.332, P = 0.004). A higher incidence of lung and liver metastases was noted for SW480 than for SW620 (P = 0.023). Uptake in SW480 and SW620 cells was significantly different between (18)F-FDG and (18)F-FLT (t = 2.507, P = 0.021, vs. t = 3.497, P = 0.002). In the small-animal PET study, the T/NT of (18)F-FDG did not differ between SW480 and SW620 tumors (2.69 +/- 0.98 vs. 3.09 +/- 1.26, P = 0.524), but the T/NT of (18)F-FLT differed significantly between SW480 and SW620 tumors (3.65 +/- 0.51 vs. 2.22 +/- 0.42, P < 0.001). Heat shock protein 27 (HSP27) expression and integrin beta(3) expression were higher, whereas vascular endothelial growth factor receptor 2 (VEGFR2) expression and Ki67 expression were lower, in SW480 cells than in SW620 cells. For SW480, metastases in lung and liver correlated significantly with (18)F-FLT uptake in tumors (r = 0.763, P = 0.005) and with expression of HSP27 (r = 0.894, P = 0.008) and integrin beta(3) (r = 0.635, P = 0.088). A correlation was also found between (18)F-FLT uptake and expression of HSP27 (r = 0.924, P = 0.004) and integrin beta(3) (r = 0.813, P = 0.025). No correlation was found between (18)F-FDG uptake in tumors and metastasis in lung and liver (r = -0.111, P = 0.388). However, there was a significantly negative correlation between (18)F-FDG uptake and the survival time of tumor-bearing mice (r = -0.500, P = 0.017), to which (18)F-FLT did not relate (r = 0.262, P = 0.182).
CONCLUSION: High uptake of (18)F-FDG and (18)F-FLT may reflect poorer survival and a higher metastatic potential for CRC in mice. Combining (18)F-FDG with (18)F-FLT PET would be helpful in better predicting the biologic behavior of CRC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837754     DOI: 10.2967/jnumed.109.064238

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Establishment of an mKate2-Expressing Cell Line for Non-Invasive Real-Time Breast Cancer In Vivo Imaging.

Authors:  Ivan Vuletic; Jinghao Liu; Honglian Wu; Yichen Ding; Yu Lei; Changhui Li; Desheng Zhu; Qiushi Ren; Hongfang Sun; Jun Li
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

2.  Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Megumi Jinguji; Nobuaki Nishimata; Shunji Shimaoka; Tohru Nihara; Kuniaki Aridome; Sadao Tanaka; Yoshihiko Fukukura; Atushi Tani; Chihaya Koriyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

3.  Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice.

Authors:  Ivan Vuletic; Kedi Zhou; Hui Li; Huichen Bai; Xiangxi Meng; Sihao Zhu; Yichen Ding; Jun Li; Hongfang Sun; Qiushi Ren
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

4.  Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Yuko Goto; Megumi Jinguji; Sadao Tanaka; Yoshihiko Fukukura; Atsushi Tani; Michiyo Higashi
Journal:  Eur Radiol       Date:  2014-08-13       Impact factor: 5.315

5.  An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.

Authors:  Heather Keen; Bernd Pichler; Damaris Kukuk; Olivier Duchamp; Olivier Raguin; Aoife Shannon; Nichola Whalley; Vivien Jacobs; Juliana Bales; Neill Gingles; Sally-Ann Ricketts; Stephen R Wedge
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

6.  Simultaneous quantification of multiple magnetic nanoparticles.

Authors:  Adam M Rauwerdink; Andrew J Giustini; John B Weaver
Journal:  Nanotechnology       Date:  2010-10-14       Impact factor: 3.874

7.  Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer.

Authors:  Jang Eun Lee; Sang Woo Kim; Jin Su Kim; Kyu Yong Choi; Won Kyung Kang; Seong Taek Oh; Ie Ryung Yoo; Sung Hoon Kim
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

8.  In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[18F]fluorothymidine PET/MRI.

Authors:  Asma Bashir; Tina Binderup; Mark Bitsch Vestergaard; Helle Broholm; Lisbeth Marner; Morten Ziebell; Kåre Fugleholm; Andreas Kjær; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-11       Impact factor: 9.236

9.  Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.

Authors:  Eliot T McKinley; Gregory D Ayers; R Adam Smith; Samir A Saleh; Ping Zhao; Mary Kay Washington; Robert J Coffey; H Charles Manning
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

10.  Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.

Authors:  Fu-Li Wang; Ye-Ying Tan; Xiang-Min Gu; Tian-Ran Li; Guang-Ming Lu; Gang Liu; Tian-Long Huo
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.